NASDAQ: MTVA
MetaVia Inc.CIK 0001638287 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade MTVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
MetaVia stockholders approve reverse stock split at 1-for-5 to 1-for-22 ratio
3 material changes detected. Sign up free to read the summary.
MetaVia reports 9.1% weight loss in Phase 1 obesity trial for DA-1726, advances pipeline
4 material changes detected. Sign up free to read the summary.
MetaVia presents Phase 1 data on dual-receptor obesity/liver drug DA-1726 at EASL
2 material changes detected. Sign up free to read the summary.
MetaVia obesity and diabetes drug data accepted for ADA 2026 conference presentations
2 material changes detected. Sign up free to read the summary.
MetaVia removes material weakness disclosures; vanoglipel Phase 2a timeline slips one year
5 material changes detected. Sign up free to read the summary.
MetaVia extends cash runway to Q4 2026 via $10M+ equity raises; warrant overhang drops 95%
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 14, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 2.1 | 2.3 |
| General and administrative | 1.9 | 1.6 |
| Total operating expenses | 4.0 | 3.9 |
| Operating income | (4.0) | (3.9) |
| Other income/(expense), net | 0.2 | 0.2 |
| Income before income taxes | (3.8) | (3.7) |
| Income tax expense/(benefit) | — | — |
| Net income | (3.8) | (3.7) |
| Basic earnings per share | (0.79) | (3.93) |
| Diluted earnings per share | (0.79) | (3.93) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 13.7 | 11.2 |
| Prepaid expenses and other current assets | 0.4 | 0.8 |
| Total current assets | 14.2 | 12.0 |
| Property, plant and equipment, net | 0.01 | 0.03 |
| Operating lease right-of-use assets, net | 0.2 | 0.1 |
| Deferred income taxes and other assets | 0.02 | 0.02 |
| TOTAL ASSETS | 14.4 | 12.1 |
| Current liabilities: | ||
| Accounts payable | 1.0 | 3.1 |
| Current portion of operating lease liabilities | 0.07 | 0.08 |
| Accrued liabilities | 3.0 | 2.4 |
| Other current liabilities | 1.1 | 2.2 |
| Total current liabilities | 5.2 | 7.7 |
| Operating lease liabilities | 0.1 | 0.04 |
| Total liabilities | 5.3 | 7.7 |
| Shareholders' equity: | ||
| Common stock | 0.01 | 0.01 |
| Capital in excess of stated value | 161.7 | 143.9 |
| Retained earnings (deficit) | (152.7) | (139.5) |
| Total shareholders' equity | 9.1 | 4.4 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 14.4 | 12.1 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (4.3) | (4.8) |
| Financing Activities: | ||
| Net cash from financing activities | 7.7 | (0.01) |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗